問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Digestive System Department

National Taiwan University Hospital Yunlin Branch  (在職)

Digestive System Department

National Taiwan University Hospital Yunlin Branch (在職)
國立臺灣大學醫學院附設醫院雲林分院

Division of General Internal Medicine

更新時間：2023-09-19

余健鈞
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

1Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

余健鈞

List

4Cases

2019-07-01 - 2026-06-30

Phase III

Active
hase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Durvalumab (IMFINZI); Bevacizumab (Avastin)

Participate Sites
9Sites

Recruiting9Sites

2018-06-01 - 2026-08-31

Phase III

Active
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation

  • Condition/Disease

    Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation

  • Test Drug

    Nivolumab

Participate Sites
12Sites

Recruiting1Sites

Terminated10Sites

林錫銘
Linkou Chang Gung Medical Foundation

Digestive System Department

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

2018-01-01 - 2020-12-31

Phase II

A Phase 2a, Open-Label, Study Evaluating the Safety and Anti-Viral Activity of ARB-001467 in Non-Cirrhotic, HBeAg-Negative Subjects with Chronic HBV Infection (Genotype A or B) in Combination with PEG-IFN α-2a and Tenofovir Disoproxil Fumarate

  • Condition/Disease

    Chronic HBV Infection (Genotype A or B)

  • Test Drug

    ARB-001467 Injection (2 mg/mL)

Participate Sites
6Sites

Terminated4Sites

彭成元
China Medical University Hospital-Taipei

未分科

林俊彥
Linkou Chang Gung Medical Foundation

Digestive System Department

2014-07-01 - 2022-12-31

Phase III

A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal DoxorubicinLTLD) in Hepatocellular Carcinoma (HCC) using standardized Radiofrequency Ablation (RFA) treatment time ≥ 45 minutes for solitary lesions ≥ 3 cm to ≤ 7 cm.

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin)

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB